Radiation Recall Dermatitis With Bruton Tyrosine Kinase Inhibitor Therapy

被引：0

作者：

Rajeh, Ahmad ^{[1
]}

Ferree, Sarah ^{[1
]}

Anadkat, Milan J. ^{[1
]}

机构：

[1] Washington Univ, Div Oncol, Sch Med, 660 S Euclid Ave,Campus Box 8123, St Louis, MO 63110 USA

来源：

JAMA DERMATOLOGY | 2024年 / 160卷 / 05期

关键词：

D O I：

10.1001/jamadermatol.2024.0124

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This case report describes a woman in her 70s with a history of breast cancer and chronic lymphocytic leukemia who presented with a painful rash of the bilateral chest extending onto the flanks.

引用

页码：577 / 578

页数：2

共 50 条

[21] Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
Wolska-Washer, Anna
Robak, Tadeusz
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 183 - 194
[22] Bruton Tyrosine Kinase Inhibitor Associated Cryptococcal Meningitis Manifesting as Stroke
Perez, Michael
Morrison, Andrew
Sloane, Kelly
NEUROLOGY, 2023, 100 (17)
[23] Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib
Steele, L.
George, C.
Cerio, R.
O'Toole, E. A.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (02) : 488 - 490
[24] The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
Crofford, Leslie J.
Nyhoff, Lindsay E.
Sheehan, Jonathan H.
Kendall, Peggy L.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (07) : 763 - 773
[25] Functional role of Bruton′s tyrosine kinase inhibitor therapy in the tumor microenvironment of B-cell malignancies
Barbarino, V.
Henschke, S.
Blakemore, S. J.
Nickel, N.
Vorholt, D.
Hallek, M.
Pallasch, C.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 220 - 221
[26] Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy
Nelson, Thomas A.
Murthy, Naina K.
Martinez-Lage Alvarez, Maria
Abramson, Jeremy
Branagan, Andrew R.
Ji, Yongli
Chen, Yi-Bin A.
Letourneau, Alyssa R.
Nahed, Brian V.
Arrillaga-Romany, Isabel C.
Wang, Nancy
Dietrich, Jorg
NEUROLOGY, 2024, 103 (09)
[27] Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
Gayko, Urte
Fung, Mann
Clow, Fong
Sun, Steven
Faust, Elizabeth
Price, Samiyeh
James, Danelle
Doyle, Margaret
Bari, Samina
Zhuang, Sen Hong
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 82 - 94
[28] Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton'S Tyrosine Kinase (BTK) Used in Cancer Therapy
Yang, Tao
Moslehi, Javid J.
Roden, Dan M.
CIRCULATION, 2015, 132
[29] Evobrutinib, a Bruton′s tyrosine kinase inhibitor, modulates microglia activity in vivo
Geladaris, A.
Torke, S.
Haselmayer, P.
Boschert, U.
Brueck, W.
Weber, M. S.
GLIA, 2023, 71 : E946 - E946
[30] An inhibitor of Bruton's tyrosine kinase (BTK) from a fungal extract.
Kawakami, T
Kawakami, Y
Hartman, SE
Kinoshita, E
Suzuki, H
Kitaura, J
Yao, L
Inagaki, N
Hata, D
Maeda-Yamamoto, M
Fukamachi, H
Nagai, H
FASEB JOURNAL, 1999, 13 (04): : A324 - A324

← 1 2 3 4 5 →